| Literature DB >> 29547850 |
Belén Pérez-Pevida1, Daniela Stefania Trifu2, Anna Kamocka3, Julia Álvarez Hernández2.
Abstract
CONTEXT: Bariatric surgery has beneficial effects on obesity and associated comorbidities such as glycaemic control in type 2 diabetes, dyslipidaemia, hypertension, and renal and hepatic function. Nevertheless, this surgery is not free of complications and possible side effects due to restrictive and/or malabsorptive related components. CASE DESCRIPTION: We report the case of a 60-year-old woman whose past medical history included morbid obesity, hypertension and Scopinaro biliopancreatic diversion (BPD) with duodenal switch in 1998. In 2015, she attended the emergency department hypotensive with bad general condition and reporting chronic constitutional symptoms. A wide variety of tests were performed including endoscopic studies as her symptoms were not immediately correlated with the BPD surgery. Finally, she was diagnosed from gastrojejunal stricture which caused her severe malnutrition. The patient underwent successful surgical management. DISCUSSION: BPD is one of the most effective surgical procedures for obesity, with an overall 5-year loss of excess body weight higher than 72%. Nonetheless, it is associated with long-term complications such as protein malnutrition and vitamin deficiencies due to malabsorption. Being surgically challenging, with high risk of nutritional complications and lifelong needed for the follow-up, BPD is rarely performed nowadays.Entities:
Keywords: Bariatric surgery; Case report; Gastrojejunal stricture; Long-term nutritional complications; Malnutrition; Scopinaro biliopancreatic diversion; Ulcer
Year: 2018 PMID: 29547850 PMCID: PMC5854923 DOI: 10.1016/j.ijscr.2018.02.040
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1Gastroscopy (A) Gastrojejunal anastomosis with ulceration. (B) Guide wire not passing the stricture during an attempt of dilatation.
Fig. 2Small bowel follows through (A) Gastrografin® given orally fills the gastric pouch but does not pass to the small intestine. (B) Gastrografin® administered via the nasojejunal tube passes into jejunum.